Mackenzie Financial’s TherapeuticsMD TXMD Stock Holding History

Mackenzie Financial’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-424	Closed	-$403K	–	1550
2022 Q1	$403K	Hold	424	–	–	﹤0.01%	1031
2021 Q4	$8K	Hold	424	–	–	﹤0.01%	1423
2021 Q3	$16K	Buy	424 +182	+75%	+$8.08K	﹤0.01%	1425
2021 Q2	$14K	Buy	+242	New	+$14.7K	﹤0.01%	1231

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Mackenzie Financial's TXMD Position: Q2 2022 in Review

Mackenzie Financial sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 424 shares — an estimated $403K sold.

Mackenzie Financial first reported a position in TXMD in Q2 2021 and held it in 4 quarters. The position peaked at $403K in Q1 2022. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

Mackenzie Financial reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
Mackenzie Financial sold 424 TherapeuticsMD shares in Q2 2022, an estimated $403K.
Mackenzie Financial first reported a position in TherapeuticsMD in Q2 2021 and held it in 4 quarters.
Mackenzie Financial's TherapeuticsMD position peaked at $403K in Q1 2022.
53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Mackenzie Financial's 13F filing for Q2 2022, filed 10 Aug 2022.